BR0011178A - Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma - Google Patents

Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma

Info

Publication number
BR0011178A
BR0011178A BR0011178-3A BR0011178A BR0011178A BR 0011178 A BR0011178 A BR 0011178A BR 0011178 A BR0011178 A BR 0011178A BR 0011178 A BR0011178 A BR 0011178A
Authority
BR
Brazil
Prior art keywords
biologically active
synthetic molecule
preparation
same
active synthetic
Prior art date
Application number
BR0011178-3A
Other languages
English (en)
Inventor
Wolf Bertling
Christian Reiser
J Rgen Walter
Original Assignee
November Ag Molekulare Medizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by November Ag Molekulare Medizin filed Critical November Ag Molekulare Medizin
Publication of BR0011178A publication Critical patent/BR0011178A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Polyamides (AREA)

Abstract

"MOLéCULA SINTéTICA BIOLOGICAMENTE ATIVA, MéTODO PARA SUA PREPARAçãO E MEDICAMENTO BASEADO NA MESMA". A presente invenção está relacionada a uma molécula sintética biologicamente ativa para a fixação de um ingrediente ativo à proteína viral 1 ( VP1 ) do vírus polyoma. De acordo com a presente invenção, a seq³ência de aminoácidos A1 que é derivada da extremidade C-terminal da proteína viral 2 ( VP2 ) ou 3 ( VP3 ) do vírus polyoma é ligada a um ingrediente ativo em uma de suas extremidades.
BR0011178-3A 1999-04-10 2000-04-03 Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma BR0011178A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19916224A DE19916224C1 (de) 1999-04-10 1999-04-10 Synthetisches biologisch aktives Molekül
PCT/DE2000/000976 WO2000061616A1 (de) 1999-04-10 2000-04-03 Fragmente des virus proteins 2 oder 3 des polymavirus als fähren für wirkstoffe

Publications (1)

Publication Number Publication Date
BR0011178A true BR0011178A (pt) 2002-05-21

Family

ID=7904139

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011178-3A BR0011178A (pt) 1999-04-10 2000-04-03 Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma

Country Status (19)

Country Link
US (2) US7011968B1 (pt)
EP (2) EP1586582A1 (pt)
JP (1) JP2002544122A (pt)
KR (1) KR100627935B1 (pt)
CN (1) CN1346366A (pt)
AT (1) ATE303401T1 (pt)
AU (1) AU768669B2 (pt)
BR (1) BR0011178A (pt)
CA (1) CA2364536A1 (pt)
CZ (1) CZ20013621A3 (pt)
DE (3) DE19916224C1 (pt)
EA (1) EA006631B1 (pt)
HU (1) HUP0200679A2 (pt)
IL (1) IL145403A0 (pt)
MX (1) MXPA01010189A (pt)
NO (1) NO20014891L (pt)
PL (1) PL355852A1 (pt)
WO (1) WO2000061616A1 (pt)
ZA (1) ZA200107658B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
DE10306789A1 (de) * 2003-02-18 2004-08-26 Responsif Gmbh Zusammensetzung zur Verabreichung an ein Lebewesen und Verfahren zur Markierung von Mitteln
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US4950599A (en) * 1987-01-29 1990-08-21 Wolf Bertling Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE19618797C2 (de) * 1996-05-10 2000-03-23 Bertling Wolf Vehikel zum Transport molekularer Substanz
US5858648A (en) * 1996-11-04 1999-01-12 Sienna Biotech, Inc. Assays using reference microparticles
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül

Also Published As

Publication number Publication date
CA2364536A1 (en) 2000-10-19
AU768669B2 (en) 2003-12-18
EP1173475B1 (de) 2005-08-31
WO2000061616A1 (de) 2000-10-19
EP1173475A1 (de) 2002-01-23
ATE303401T1 (de) 2005-09-15
DE50011068D1 (de) 2005-10-06
EP1586582A1 (de) 2005-10-19
MXPA01010189A (es) 2003-07-21
US7011968B1 (en) 2006-03-14
NO20014891L (no) 2001-11-07
JP2002544122A (ja) 2002-12-24
KR100627935B1 (ko) 2006-09-22
CZ20013621A3 (cs) 2002-05-15
EA006631B1 (ru) 2006-02-24
DE10080849D2 (de) 2002-06-27
US20070009921A1 (en) 2007-01-11
EA200101066A1 (ru) 2002-04-25
CN1346366A (zh) 2002-04-24
KR20020007361A (ko) 2002-01-26
HUP0200679A2 (en) 2002-06-29
DE19916224C1 (de) 2000-06-21
ZA200107658B (en) 2002-07-22
AU4285000A (en) 2000-11-14
NO20014891D0 (no) 2001-10-08
PL355852A1 (en) 2004-05-31
IL145403A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
ATE298561T1 (de) Orale dareichungsform
BR9812068A (pt) Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
DK0566641T3 (da) Anvendelse af human IGF-I.
CA2181150A1 (en) Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
DK0692970T3 (da) Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli
BR0214188A (pt) Anticorpos monoclonais contra vìrus da hepatite e ou seus fragmentos com atividade de ligação e uso dos mesmos
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
BR9712202A (pt) Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.
BR0006927A (pt) Dispositivo para a aplicação de um produto sobre as fibras queratìnicas, notadamente os cìlios ou as sobrancelhas
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR0013638A (pt) Novas moléculas semelhantes a interferon beta
BR0011178A (pt) Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma
DE69531004D1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR9607628A (pt) Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero
BR0112515A (pt) Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
KR910002899A (ko) 혈조절 펩타이드
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
DE69430295D1 (de) Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe
BR9712306A (pt) Processo para preparação de um preparado de igm para aplicação endovenosa

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/005 (2006.01), A61K 47/62 (2017.01), A61K